Day One Biopharma shares surge 20.69% premarket on strong 2025 OJEMDA revenue and 2026 guidance.

Day One Biopharmaceuticals (DAWN) surged 20.69% in premarket trading following the announcement of preliminary 2025 net product revenue of $155.4 million for OJEMDA, a 172% year-over-year increase. The company also projected 2026 U.S. net product revenue between $225 million and $250 million, reflecting 53% growth at the midpoint. Strong quarterly growth of 37% in Q4 2025 and robust prescription volumes of 1,394 underscored the momentum. Analysts cited the revenue performance and future guidance as key drivers, aligning with the stock’s premarket rally. The upbeat forecast, coupled with advancing clinical trials for FIREFLY-2, reinforced optimism about OJEMDA’s commercial potential and long-term growth prospects.